Stock Screener App

無料 - Play StoreApp Store

インストールインストール

CGEM

$14.930.67%-0.10

Cullinan Therapeutics Inc (CGEM)

Date: O: H: L: C: Vol:

Cullinan Therapeutics Inc (CGEM) 最新ニュース

Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA - GlobeNewswire Inc.

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 6.7% - Still a Buy? - MarketBeat

Cullinan Therapeutics, Taiho Oncology Report 30.2% Intracranial Response Rate in Phase 2 Cancer Trial - Yahoo Finance

Responses in the brain to an experimental lung cancer drug lasted a median 9.7 months. - Stock Titan

Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance Singapore

Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance UK

Ellsworth Advisors LLC Buys New Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Cullinan Therapeutics (CGEM) Ticks Higher: Shares Gain 1.31% to $16.25 - Elliott Wave Count - https://www.siam.in/

Form 8K Cullinan Therapeutics, Inc For: 2 October By Investing.com - Investing.com South Africa

Up to $100M hinges on first-line approval as Cullinan (CGEM) starts a lung cancer drug submission. - Stock Titan

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts - MarketBeat

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance UK

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - GlobeNewswire Inc.

Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at BTIG Research - MarketBeat

Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia

510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Stocktwits

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1% - Here's What Happened - MarketBeat

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire Inc.

Cullinan Therapeutics (NasdaqGS:CGEM) Stock Price - Simply Wall Street

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews

Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat

EGFR-NSCLC Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innova - Barchart.com

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Investing News Network

Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event - Quiver Quantitative

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - The Manila Times

Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire

Cullinan Therapeutics CSO Jennifer Michaelson Executes 8,000 Share Sale Under 10b5-1 Plan - Kalkine Media

Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat

Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan - Stock Titan

171,031 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Bank of New York Mellon Corp - MarketBeat

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Corient Private Wealth LP Takes $970,000 Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

The Manufacturers Life Insurance Company Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

CGEM Should I Buy - Intellectia AI

Cullinan Therapeutics (NASDAQ:CGEM) Upgraded to Hold at Wall Street Zen - MarketBeat

Moore Capital Management LP Raises Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Algert Global LLC Sells 72,880 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat

BlackRock Inc. Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Elmind Capital LP Purchases New Shares in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Boone Capital Management LLC Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Cullinan Therapeutics shows strong multi-asset pipeline with key drug milestones boosting funding prospects. - Pluang

Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Deutsche Bank AG Purchases Shares of 382,840 Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat

Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest Session - Earnings Yield Analysis - vinanet.vn

Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest Session - Capex Guidance - vinanet.vn

CGEMに類似

MLTX$11.472.63%

RIGL$50.531.52%

ODTX$19.530.05%

GLUE$10.631.21%